Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy

NCT02325414 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02325414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02325414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
August 25, 2020
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute spinal cord injury, bone loss, osteoporosis, spinal cord injury